Loading...
Linezolid: a promising agent for the treatment of multiple and extensively drug-resistant tuberculosis
Fermeli, Dionysia D. Marantos, Theodoros D. Liarakos, Alexandros-Leonidas D. Panayiotakopoulos, George D. Dedes, Vasileios K. Panoutsopoulos, Georgios I.
Fermeli, Dionysia D.
Marantos, Theodoros D.
Liarakos, Alexandros-Leonidas D.
Panayiotakopoulos, George D.
Dedes, Vasileios K.
Panoutsopoulos, Georgios I.
Citations
Altmetric:
Affiliation
General Hospital of Sparta, Greece; University of Athens, Attikon General Hospital, Athens, Greece; George Eliot Hospital, Nuneaton; University of Patras, Greece; University of Peloponnese, Tripolis, Greece
Other Contributors
Publication date
2020-09-30
Collections
Files
Loading...
Main article
Adobe PDF, 381.51 KB
Research Projects
Organizational Units
Journal Issue
Abstract
Tuberculosis is a severe, infectious disease caused by Mycobacterium tuberculosis. The aim of this review was to present the efficacy of linezolid as an agent against multidrug and extensively drug-resistant tuberculosis as gathered from many recent research studies. Linezolid seems to have strongly the potential of being used as an anti-tuberculosis agent because it blocks bacterial ribosomal protein synthesis. Nevertheless caution is required because of the adverse effects it causes, especially when the linezolid daily dosage exceeds 600 mg. The most severe adverse effects include anemia, peripheral neuropathy, optic neuropathy and thrombocytopenia. Still, more trials and research need to be done in order to gather more information and value the cost-benefit dosage of the treatment.
Citation
Fermeli DD, Marantos TD, Liarakos AD, Panayiotakopoulos GD, Dedes VK, Panoutsopoulos GI. Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis. Folia Med (Plovdiv). 2020 Sep 30;62(3):444-452. doi: 10.3897/folmed.62.e48742.
Type
Article